by 
Anti-neprilysin inhibitors help reduce blood pressure and heart failure by blocking the breakdown of natriuretic peptides which have effects on vasodilation, natriuresis and diuresis. Common anti-neprilysin medications include sacubitril/valsartan which is used in the treatment of heart failure.
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing Prevalence of Cardiovascular Diseases: Cardiovascular diseases are the leading cause of death globally and conditions like heart failure, myocardial infarction and high blood pressure are on the rise. According to World Health Organization, cardiovascular diseases accounted for over 17 million deaths in 2015 which is estimated to grow to over 23.6 million by 2030. Rise in various modifiable and non-modifiable risk factors such as obesity, diabetes, sedentary lifestyles etc. are contributing to the increased prevalence of cardiovascular conditions which is expected to drive the demand for anti-neprilysin drugs for treatment.
New Product Launches and Approvals: Key players in the market are focusing on developing innovative drug formulations and combinations for improved efficacy and safety in cardiovascular treatment. For instance, in 2017, FDA approved sacubitril/valsartan (Entresto) for treatment of heart failure. In 2020, BIOPROJET received approval for sacubitril/valsartan in South Korea. Such new product launches and approvals are helping expand the indications and boost adoption of anti-neprilysin drugs among patients and healthcare practitioners.
Segment Analysis
The global anti-neprilysin market is divided into segments based on drug type and application. Based on drug type, the sacubitril/valsartan segment holds the dominant market share as it is the only approved drug for treating heart failure. Sacubitril/valsartan significantly reduces cardiovascular deaths and hospitalization for heart failure. Based on application, the chronic heart failure segment dominates as anti-neprilysin drugs are primarily used for treatment of chronic heart failure.
PEST Analysis
Political: The regulations around clinical trials and drug approvals play a key role in market growth. Supportive regulations can accelerate drug development and market access.
Economic: Rising healthcare expenditures and growing burden of cardiovascular diseases will drive demand. However, pricing pressures can affect market revenues.
Social: Increasing awareness about therapeutic options for heart failure management is positively impacting the market. Advanced treatments can help improve quality of life.
Technological: Ongoing R&D is exploring new molecules and drug delivery mechanisms. This will increase treatment effectiveness and drive compliance.
Key Takeaways
The global anti-neprilysin market is expected to witness high growth over the forecast period aided by increasing heart failure prevalence and improved treatment outcomes. The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Regionally, North America dominates currently owing to developed healthcare systems and high adoption of novel therapies. Europe is also a sizable market driven by supportive reimbursement structures. Asia Pacific is anticipated to be the fastest growing region in the anti-neprilysin market led by expanding patient pools, rising medical tourism, and improving access in major countries. China, Japan and India offer immense growth opportunities.
Key players
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. Novartis has a major share with its sacubitril/valsartan drug Entresto for treatment of chronic heart failure. Other players are focusing on developing new drug candidates.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
